Slika omota

High-Risk Localized and Locally Advanced Prostate Cancer

Around 20%–30% of nonmetastatic prostate cancer patients have high-risk localized disease. The best treatment for high-risk localized disease is still unclear, and the reliability of the definition of “high-risk” may need to be validated first. Although recent advances in radiotherapy for prostate c...

Cijeli opis

Spremljeno u:
Format: Online
Jezik:engleski
Izdano: MDPI - Multidisciplinary Digital Publishing Institute 2023
Teme:
imaging modality
&nbsp
oligometastasis
radical prostatectomy
lymph node dissection
brachytherapy
hormonal therapy
neoadjuvant/adjuvant therapy
quality of life
local invasion
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TC Biochemical engineering::TCB Biotechnology
Online pristup:ONIX_20230808_9783036581682_54
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
Sažetak:Around 20%–30% of nonmetastatic prostate cancer patients have high-risk localized disease. The best treatment for high-risk localized disease is still unclear, and the reliability of the definition of “high-risk” may need to be validated first. Although recent advances in radiotherapy for prostate cancer have yielded excellent long-term results, even in high-risk localized disease, there are no studies directly comparing it with local treatment options, such as prostatectomy. To address current challenges in high-risk localized and locally advanced prostate cancer, 12 original and 3 review articles covering aspects from basic research to clinical trials are published in this Special Issue.

Slični predmeti